🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Heidelberg
Clinical trial register · Germany

Clinical Trials in Heidelberg, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University Hospital Heidelberg50 AstraZeneca33 Janssen Research & Development, LLC27 Merck Sharp & Dohme LLC18 Hoffmann-La Roche17
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Heidelberg

627 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960Multiple Myeloma
DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone
AbbVie
Phase 1/2
325
Heidelberg, Munich, Würzburg, Hamburg
2025-07-23
Recruiting
State of In-hospital Disaster Protection at Children's Hospitals in Germany
NCT07766941Hospital Emergency and Operations Planning, Pediatric Hospital
University Hospital Heidelberg
Observational
380
Heidelberg
2025-07-22
Recruiting
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)
NCT05690048Immunotherapy, HCC - Hepatocellular Carcinoma
DrugsVancomycin·Atezolizumab·Bevacizumab
Michael Dill
Phase 2
48
Heidelberg, Augsburg, Essen, Mannheim, Regensburg, Tübingen, Ulm
2025-07-16
Active, closed
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
NCT07105488Atopic Dermatitis (AD)
DrugBFB759
Bluefin Biomedicine, Inc.
Phase 2
225
Bad Bentheim, Berlin, Göttingen, Heidelberg, Münster
2025-07-15
Recruiting
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
NCT06898515Acute Decompensated Heart Failure
DrugFurosemide
Reprieve Cardiovascular, Inc
Phase 3
400
Giessen, Hanover, Heidelberg, Jena
2025-07-14
Recruiting
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
NCT06838676Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG, Refractory DIPG, Recurrent DIPG
DrugACT001
Nationwide Children's Hospital
Phase 2
60
Heidelberg
2025-07-10
Recruiting
A Randomized Controlled Study of the NEURESCUE Device as an Adjunct to Advanced Cardiac Life Support
NCT06793033Cardiac Arrest (CA), Cardiopulmonary Arrest
neurescue
Not applicable
84
Berlin, Heidelberg
2025-07-07
Recruiting
Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
NCT07145450PDAC
Anocca AB
Phase 1/2
96
Berlin, Dresden, Heidelberg, Leipzig, München, Tübingen
2025-07-03
Recruiting
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
NCT06863272Castration-Resistant Prostatic Cancer, Metastasis
DrugsOpevesostat·Ifinatamab Deruxtecan·Abiraterone·Enzalutamide
Merck Sharp & Dohme LLC
Phase 1/2
360
Heidelberg, Ulm, Jena, Hamburg
2025-07-03
Active, closed
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
NCT06649695AL Amyloidosis
DrugTeclistamab
European Myeloma Network B.V.
Phase 2
30
Essen, Heidelberg, Würzburg
2025-07-02
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903Transthyretin Amyloidosis With Cardiomyopathy
DrugNucresiran
Alnylam Pharmaceuticals
Phase 3
1,750
Berlin, Cologne, Dresden, Göttingen, Hanover, Heidelberg, Leipzig, Magdeburg
2025-07-02
Recruiting
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
NCT06979375Heart Failure
DrugCDR132L
Novo Nordisk A/S
Phase 2
200
Berlin, Dresden, Essen, Frankfurt am Main, Halle, Hanover, Heidelberg, Kiel
2025-06-30
Active, closed
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
NCT06979531Primary Sjögren's Syndrome
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
180
Bad Doberan, Hamburg, Hanover, Heidelberg, Munich
2025-06-30
Recruiting
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362Heart Failure
DrugCDR132L
Novo Nordisk A/S
Phase 2
200
Berlin, Dresden, Essen, Frankfurt am Main, Halle, Hanover, Heidelberg, Kiel
2025-06-27
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281Relapsing Multiple Sclerosis
DrugsRemibrutinib·Ocrelizumab
Novartis Pharmaceuticals
Phase 3
400
Berlin, Bochum, Erbach im Odenwald, Essen, Greifswald, Heidelberg, Münster, Ulm
2025-06-23
Recruiting
PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]
NCT06923111Sickle Cell Disease
Nova Laboratories Limited
Observational
180
Hamburg, Heidelberg
2025-06-09
Recruiting
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06902558Autosomal Dominant Polycystic Kidney Disease
Calico Life Sciences LLC
Phase 2
240
Heidelberg, Munich, Hanover, Cologne, Berlin
2025-06-09
Recruiting
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125Dravet Syndrome
DrugZorevunersen
Stoke Therapeutics, Inc
Phase 3
170
Berlin, Bonn, Frankfurt, Friedberg, Heidelberg, München
2025-06-04
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
DrugsBleximenib·Azacitidine·Venetoclax
Janssen Research & Development, LLC
Phase 3
600
Augsburg, Cologne, Dresden, Frankfurt, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel
2025-06-04
Recruiting
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
NCT06961006Malignant Melanoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
160
Heidelberg, Frankfurt am Main, Cologne, Essen, Hamburg
2025-05-29
Recruiting
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
NCT06994143Rheumatoid Arthritis (RA
DrugCLN-978
Cullinan Therapeutics Inc.
Phase 1
37
Erlangen, Heidelberg
2025-05-19
Recruiting
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993Atopic Dermatitis
Novartis Pharmaceuticals
Phase 2
224
Frankfurt am Main, Mainz, Bad Bentheim, Dresden, Hamburg, Heidelberg, Magdeburg, Münster
2025-05-16
Active, closed
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
NCT06993610Hidradenitis Suppurativa (HS)
Zura Bio Inc
Phase 2
225
Bad Bentheim, Bochum, Darmstadt, Dresden, Hamburg, Heidelberg, München, Münster
2025-05-16
Recruiting
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
NCT07003425Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
350
Heidelberg, Tübingen, Augsburg, München, Blankenfelde-Mahlow, Darmstadt, Frankfurt am Main, Bad Bentheim
2025-05-14
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
425
Heidelberg, Potsdam
2025-05-12
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
DrugAcoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3
587
Berlin, Heidelberg, Mainz
2025-05-12
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
DrugFelzartamab
Biogen
Phase 3
454
Heidelberg, Villingen-Schwenningen, Frankfurt am Main, Mainz, Dresden, Leipzig, Berlin
2025-05-08
Recruiting
Endothelial Dysfunction for Prognosis In Patients With preeClampSia
NCT06912477Preeclampsia (PE), Hypertensive Disorder of Pregnancy
Heidelberg University
Observational
385
Heidelberg
2025-05-08
Recruiting
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
NCT07227246Intracerebral Hemorrhage
DrugRecombinant Factor VIIa
Joseph Broderick, MD
Phase 3
350
Heidelberg, Erlangen, Frankfurt am Main, Augsburg, Berlin, Hamburg, Tübingen
2025-05-06
Recruiting
Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
NCT06916507Parkinson's Disease
AbbVie
Observational
125
Allensbach, Heidelberg, Tübingen, Ulm, Wolfach, Erlangen, Ingolstadt, Munich
2025-05-06
Recruiting
DV 100 as a Framework for the Hospital Incident Command System
NCT06913010Disaster, Crisis Response Plan, Emergency, Communication
University Hospital Heidelberg
Observational
20
Heidelberg
2025-04-29
Active, closed
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
NCT06814145Hypertension, Pulmonary
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
440
Heidelberg, München, Giessen, Cologne, Mainz, Dresden, Berlin
2025-04-16
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671CLL, Chronic Lymphocytic Leukemia
DrugsIdelalisib·Tacabrutideg·Bendamustine·Venetoclax
BeOne Medicines
Phase 3
250
Augsburg, Berlin, Chemnitz, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2025-04-10
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
DrugsCDK4/6i·Inavolisib·Letrozole
Hoffmann-La Roche
Phase 3
450
Cologne, Dresden, Essen, Hamburg, Hanover, Heidelberg, Koblenz, Langen
2025-04-09
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
Freiburg im Breisgau, Heidelberg, Ulm
2025-04-03
Active, closed
Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma
NCT06731803Esophagogastric Adenocarcinoma
DrugTrastuzumab deruxtecan
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1/2
36
Berlin, Chemnitz, Essen, Frankfurt am Main, Halle, Hamburg, Heidelberg, Jena
2025-03-25
Active, closed
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone·Enzalutamide·Docetaxel
Celgene
Phase 3
960
Nürtingen, München, Lübeck, Jena, Bonn, Essen, Hamburg, Heidelberg
2025-03-13
Active, closed
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
NCT06903338Viral Hepatitis
DrugsTobevibart·Elebsiran
Vir Biotechnology, Inc.
Phase 3
124
Frankfurt, Hanover, Heidelberg
2025-03-12
Recruiting
177Lu-DOTATATE for Recurrent Meningioma
NCT06326190Recurrent Meningioma
DrugsLuTate·Lutathera
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
136
Essen, Frankfurt, Heidelberg, München
2025-03-10
Recruiting
Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
NCT06764706Ulcerative Colitis
AbbVie
Observational
200
Heidelberg, Potsdam, Tostedt, Hanover, Schwerin, Ahaus, Bochum, Cologne
2025-02-27
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
726
Berlin, Chemnitz, Dresden, Frankfurt am Main, Hamburg, Heidelberg, Leipzig, München
2025-02-27
Recruiting
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949Sjögren's Syndrome
DrugDazodalibep
Amgen
Phase 3
844
Heidelberg, Bad Doberan, Greifswald Hansestadt, Hamburg
2025-02-25
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Extensive-Stage Small Cell Lung Cancer
DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin
Bristol-Myers Squibb
Phase 3
530
Frankfurt am Main, Oldenburg, Cologne, Halle, Bad Berka, Gauting, Großhansdorf, Heidelberg
2025-02-25
Active, closed
Post Market Registry for GORE® TAG® Thoracic Branch Endoprosthesis
NCT06507865Aneurysm, Dissection, Aortic, TAA Thoracoabdominal Aortic Aneurysm, Thoracic Aortic Aneurysm
W.L.Gore & Associates
Observational
155
Hamburg, Heidelberg, Kiel, Münster
2025-02-20
Recruiting
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
NCT06830720Breast Neoplasms
DrugsRibociclib·Abemaciclib
Novartis Pharmaceuticals
Observational
3,250
Baden-Baden, Filderstadt, Freudenstadt, Heidelberg, Heidenheim, Konstanz, Mannheim, Nürtingen
2025-02-20
Recruiting
Fruquintinib in Patients With Metastatic Colorectal Cancer
NCT06787105Metastatic Colorectal Cancer (mCRC)
iOMEDICO AG
Observational
150
Biberach, Freiburg im Breisgau, Heidelberg, Ravensburg, Schorndorf, Weinheim, Aschaffenburg, Fürth
2025-02-17
Recruiting
Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial
NCT06456983Schizophrenia, Treatment Resistant Schizophrenia
Central Institute of Mental Health, Mannheim
Not applicable
140
Aachen, Augsburg, Göppingen, Göttingen, Hanover, Heidelberg, Ingolstadt, Mainz
2025-02-14
Recruiting
Study of Olutasidenib and Temozolomide in HGG
NCT06161974High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV
DrugOlutasidenib
Rigel Pharmaceuticals
Phase 2
60
Heidelberg
2025-02-01
Active, closed
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
NCT06478212IDH1-mutant Glioma, IDH2-mutant Glioma
DrugsVorasidenib·Temozolomide
Institut de Recherches Internationales Servier
Phase 1/2
51
Heidelberg, Mannheim, Regensburg
2025-01-22
Recruiting
Lumbar Drainage of Intraventricular Hemorrhage
NCT06510842Intraventricular Hemorrhage, Lumbar Drainage, External Ventricular Drainage
University Hospital Heidelberg
Not applicable
354
Heidelberg, München, Augsburg, Berlin, Düsseldorf, Frankfurt, Göttingen, Mainz
2025-01-16
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
DrugOcrelizumab
Amgen
Phase 3
152
Bad Homburg, Böblingen, Dresden, Ebersberg, Essen, Hamburg, Heidelberg, Leipzig
2025-01-13
Recruiting
The REDUCE EU Study - Endobronchial Thermal Liquid Ablation (ETLA) for the Treatment of Emphysema
NCT06655428Emphysema or COPD, Emphysema, Emphysema, Pulmonary, COPD
Morair Medtech, LLC
Not applicable
30
Berlin, Gauting, Hamburg, Heidelberg
2025-01-10
Recruiting
Risk-stratified Testing for Safe Removal of Penicillin Allergy Labels
NCT06755281Penicillin Allergy, Hypersensitivity, Immediate, Hypersensitivity, Delayed, Hypersensitivity Response
Deniz Göcebe
Not applicable
100
Heidelberg
2025-01-08
Recruiting
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction
Cytokinetics
Phase 3
1,800
Heidelberg, München, Würzburg, Hamburg, Erfurt, Jena, Mainz, Bad Nauheim
2024-12-19
Recruiting
Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
NCT06456359Desmoplastic Small Round Cell Tumor, Synovial Sarcoma
University Hospital Heidelberg
Phase 2
28
Heidelberg, Stuttgart, Essen
2024-12-19
Active, closed
NG004 in Spinal Cord Injury Patients
NCT06817577Acute Spinal Cord Injury (SCI), Spinal Cord Diseases, Central Nervous System Diseases, Nervous System Diseases
DrugNG004
NovaGo Therapeutics AG
Phase 1
20
Bayreuth, Halle, Heidelberg, Murnau am Staffelsee
2024-12-18
Recruiting
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
NCT06726720Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
AstraZeneca
Observational
300
Berlin, Dresden, Frankfurt am Main, Halle, Hamburg, Hanover, Heidelberg, Kassel
2024-12-16
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Irinotecan·Adrucil
Janssen Research & Development, LLC
Phase 3
700
Berlin, Frankfurt am Main, Heidelberg, Mainz, Munich
2024-12-12
Active, closed
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
NCT06784648Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent
DrugsIpilimumab·Keytruda·Pembrolizumab
BioInvent International AB
Phase 1/2
35
Berlin, Essen, Heidelberg, Mannheim
2024-12-11
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
350
Heidelberg, Lüneburg, Potsdam
2024-12-11
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858Candidemia, Candidiasis, Invasive
DrugsCaspofungin·Fosmanogepix·Fluconazole
Basilea Pharmaceutica
Phase 3
450
Ulm, Regensburg, Frankfurt am Main, Giessen, Cologne, Heidelberg
2024-12-11
Active, closed
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide
Amgen
Phase 3
707
Berlin, Dresden, Düsseldorf, Essen, Hamburg, Heidelberg, Jena, Lübeck
2024-12-09
Active, closed
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686Idiopathic Pulmonary Fibrosis (IPF)
Vicore Pharma AB
Phase 2
378
Freiburg im Breisgau, Heidelberg, Tübingen, Frankfurt am Main, Immenhausen, Hanover, Essen, Berlin
2024-12-09
Active, closed
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
NCT06534983Muscle-invasive Urothelial Carcinoma
DrugsAutogene cevumeran·Nivolumab
Hoffmann-La Roche
Phase 2
62
Berlin, Heidelberg, Herne, Stuttgart
2024-12-09
Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245Patients With Non-Small Cell Lung Cancer
DrugsTedopi·Docetaxel
OSE Immunotherapeutics
Phase 3
363
Heidelberg, Stuttgart, Gauting, München, Kassel, Aachen, Bonn, Essen
2024-12-03
By invitation
PIECES - Towards Large-Scale Adaptation and Tailored Implementation of Primary Cancer Prevention Programs
NCT06718322Focus of Study: Tailored Implementation
Hidde van der Ploeg
Not applicable
100
Berlin, Hanover, Heidelberg
2024-12-01
Active, closed
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914Migraine
AbbVie
Observational
1,314
Heidelberg, Tübingen, Hoppegarten, Bad Homburg, Oldenburg, Greifswald, Siegen, Velbert
2024-11-26
Active, closed
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
DrugsDocetaxel·Pembrolizumab
Genmab
Phase 3
191
Esslingen am Neckar, Heidelberg, Göttingen, Hanover, Mainz, Dresden, Halle, Großhansdorf
2024-11-25
Recruiting
Perturbation-Based Treadmill Training to Prevent Unrecovered Falls in Geriatric Patients
NCT06652828Fall Prevention, Exercise, Geriatrics, Cognitive Impairment
University of Oldenburg
Not applicable
396
Heidelberg, Herne, Oldenburg
2024-11-25
Recruiting
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
NCT06690775Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
DrugsTORL-1-23·Pegfilgrastim
TORL Biotherapeutics, LLC
Phase 2
230
Heidelberg, Erlangen, Berlin
2024-11-20
Recruiting
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
NCT06631092Triple Negative Breast Cancer
DrugDNA vaccine
NEC Bio B.V
Phase 1/2
28
Erlangen, Heidelberg
2024-11-20
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
DrugQuizartinib
Daiichi Sankyo
Phase 3
700
Alzenau in Unterfranken, Berlin, Braunschweig, Dresden, Essen, Hanover, Heidelberg, Kiel
2024-11-19
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Berlin, Bochum, Cologne, Dresden, Frankfurt, Heidelberg, Homburg, Landshut
2024-11-12
Recruiting
Safety and Efficacy Evaluation of the Ceretrieve Device in the Treatment of AIS Patients
NCT06733246Acute Ischemic Stroke
Ceretrieve Ltd.
Not applicable
132
Heidelberg
2024-11-12
Recruiting
Adjuvant Tebentafusp in High Risk Ocular Melanoma
NCT06246149Uveal Melanoma
DrugTebentafusp
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
290
Berlin, Hamburg, Heidelberg
2024-11-11
Recruiting
A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
NCT06712628Moderate to Severe Rheumatoid Arthritis
AbbVie
Observational
678
Freiburg im Breisgau, Heidelberg, Tübingen, Ulm, Amberg, Augsburg, Marktredwitz, Munich
2024-11-07
Recruiting
Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)
NCT06784791Lung Cancer (NSCLC)
DrugsCarboplatin/pemetrexed·Amivantamab
University Hospital, Essen
Phase 2
20
Heidelberg, Essen
2024-11-06
Recruiting
Assessing Pancreatic Fistula Rates After Distal Pancreatectomy Using AEON Endostapler
NCT06764134Pancreas; Fistula, Pancreas Cancer, Pancreatic Disease, Surgery-Complications
University Hospital Heidelberg
Observational
110
Heidelberg
2024-11-01
Recruiting
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593Moderately to Severely Active Crohn Disease
DrugObefazimod
Abivax S.A.
Phase 2
212
Berlin, Brandenburg an der Havel, Erlangen, Frankfurt am Main, Hamburg, Hanover, Heidelberg, Kiel
2024-10-30
Active, closed
A Study of Mosliciguat in PH-ILD
NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 2
135
Heidelberg, München, Dresden, Halle
2024-10-29
Recruiting
Microbiological and Clinical Effects of Pre- and Probiotics in Non-Surgical Periodontal Therapy
NCT07443410Periodontitis, Adult, Periodontitis (Stage 3), Periodontitis Stage IV
University Hospital Heidelberg
Not applicable
60
Heidelberg
2024-10-25
Recruiting
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
NCT06649110Healthy Volunteers, Pulmonary Arterial Hypertension
Novartis Pharmaceuticals
Phase 1/2
232
Regensburg, Dresden, Berlin, Giessen, Greifswald, Heidelberg, Homburg
2024-10-24
Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422Carcinoma, Non-Small-Cell Lung
DrugsIntismeran autogene·Pemetrexed·Gemcitabine·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
680
Heidelberg, Stuttgart, Kempten (Allgäu), Giessen, Oldenburg, Eschweiler, Münster, Mainz
2024-10-21
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Erbitux·Amivantamab·Irinotecan
Janssen Research & Development, LLC
Phase 3
1,000
Berlin, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg, Mainz
2024-10-18
Active, closed
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06625320Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsLiposomal Irinotecan·Leucovorin·Irinotecan·Adrucil
Revolution Medicines, Inc.
Phase 3
500
Berlin, Heidelberg, München, Ulm
2024-10-16
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Berlin, Bochum, Cologne, Dresden, Erlangen, Frankfurt, Heidelberg, Homburg
2024-10-14
Active, closed
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
NCT06516952Prurigo Nodularis
DrugPovorcitinib
Incyte Corporation
Phase 3
349
Aachen, Bad Bentheim, Berlin, Dortmund, Halle, Hamburg, Heidelberg, Leipzig
2024-10-10
Active, closed
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors
NCT06631079Solid Tumor
NEC Bio B.V
Phase 1/2
20
Berlin, Heidelberg, Munich
2024-10-07
Recruiting
Efficacy of INM004 in Children With STEC-HUS
NCT06389474Hemolytic-Uremic Syndrome
Inmunova S.A.
Phase 3
220
Berlin, Cologne, Heidelberg
2024-10-05
Active, closed
Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of HDV Infection
NCT06603311Compensated Liver Disease (Disorder), Hepatitis D, Chronic
Hannover Medical School
Not applicable
20
Heidelberg, Frankfurt am Main, Hanover, Berlin
2024-09-30
Recruiting
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
NCT06539507Netherton Syndrome
BioCryst Pharmaceuticals
Phase 1
78
Heidelberg
2024-09-26
Active, closed
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Adagrasib·Sotorasib
Hoffmann-La Roche
Phase 3
338
Berlin, Cologne, Essen, Esslingen am Neckar, Gauting, Großhansdorf, Heidelberg, Hemer
2024-09-23
Recruiting
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT06469944Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Xeloda·Sacituzumab tirumotecan·Leucovorin
Merck Sharp & Dohme LLC
Phase 1/2
160
Heidelberg, Erdgeschoss, Düsseldorf
2024-09-20
Active, closed
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer
DrugsAnvumetostat·Sotorasib·Pemetrexed·Paclitaxel
Amgen
Phase 1
49
Essen, Heidelberg, Würzburg
2024-09-17
Recruiting
Apnoeic Oxygenation During Pediatric Tracheal Intubation
NCT06576596Anesthesia, Airway Complication of Anesthesia, Anesthesia; Adverse Effect
University Hospital Heidelberg
Not applicable
200
Heidelberg
2024-09-09
Recruiting
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801Pulmonary Arterial Hypertension
DrugSeralutinib
Gossamer Bio USA, Inc.
Phase 3
330
Cologne, Dresden, Giessen, Heidelberg, Munich, München, Würzburg
2024-09-03
Recruiting
Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
NCT06175845Cholangiocarcinoma, Klatskin Tumor, Bile Duct Cancer, Liver Cancer
Universitätsklinikum Hamburg-Eppendorf
Not applicable
130
Berlin, Bonn, Chemnitz, Essen, Hamburg, Hanover, Heidelberg, Lübeck
2024-08-30
Recruiting
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
NCT05843253High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma
DrugsEverolimus·Ribociclib·Temozolomide
Nationwide Children's Hospital
Phase 2
120
Heidelberg
2024-08-22
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Cologne, Frankfurt, Gauting, Großhansdorf, Hamburg, Heidelberg, Mainz, Münster
2024-08-22
Active, closed
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
NCT06577025Multiple Myeloma
DrugsCilta-cel·Talquetamab·Teclistamab·Bortezomib
Janssen Research & Development, LLC
Phase 2
43
Heidelberg, Tübingen, Würzburg
2024-08-20
Rows per page Showing 101–200 of 627
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/heidelberg?page=2

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 627 of those studies with a site in Heidelberg.

How many clinical trials are recruiting in Heidelberg?

333 of the 627 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 16 have not yet opened recruitment, 272 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.